Tag: alpha-1 liver disease

Alnylam, Dicerna form RNAi collaboration for alpha-1 liver disease

pharmanewsdaily- April 8, 2020

Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are joining forces to develop and commercialize ribonucleicacid interference therapies (RNAi therapeutics) for the treatment of alpha-1 antitrypsin deficiency-associated liver ... Read More